Limbic encephalitis and type 1 diabetes with glutamic acid decarboxylase 65 (GAD65) autoimmunity: improvement with high-dose intravenous immunoglobulin therapy. - Inria - Institut national de recherche en sciences et technologies du numérique Accéder directement au contenu
Article Dans Une Revue Diabetes & Metabolism Année : 2012

Limbic encephalitis and type 1 diabetes with glutamic acid decarboxylase 65 (GAD65) autoimmunity: improvement with high-dose intravenous immunoglobulin therapy.

M. Lopez-Sublet
  • Fonction : Auteur
H. Bihan
  • Fonction : Auteur
G. Reach
  • Fonction : Auteur
A. Didelot
  • Fonction : Auteur
J.-J. Mourad
  • Fonction : Auteur
A. Krivitzky
  • Fonction : Auteur
R. Dhote
  • Fonction : Auteur

Résumé

Glutamic acid decarboxylase antibodies (GAD-abs) are an immunological factor involved in type 1 diabetes and other diseases involving the central nervous system. This report is of a patient with type 1 diabetes and a rare case of non-paraneoplastic limbic encephalitis mediated by anti-GAD65 antibodies that improved with the use of immunosuppressive drugs.

Dates et versions

hal-00793692 , version 1 (22-02-2013)

Identifiants

Citer

M. Lopez-Sublet, H. Bihan, G. Reach, Sophie Dupont, A. Didelot, et al.. Limbic encephalitis and type 1 diabetes with glutamic acid decarboxylase 65 (GAD65) autoimmunity: improvement with high-dose intravenous immunoglobulin therapy.. Diabetes & Metabolism, 2012, 38 (3), pp.273-5. ⟨10.1016/j.diabet.2012.02.005⟩. ⟨hal-00793692⟩
57 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More